Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Spinal disorder
Clinical narrative: Transverse myelitis; This spontaneous case was reported by a patient and describes the occurrence of MYELITIS TRANSVERSE (Transverse myelitis) in a 41-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch no. 202G23-2A) for COVID-19 prophylaxis.     Concurrent medical conditions included Myelin oligodendrocyte glycoprotein antibody-associated disease (Further bloodwork revealed that I have a (previously undiagnosed and asymptomatic) antibody disorder called MOGAD.).    On 11-Nov-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Intramuscular use) 1 dosage form. On 15-Nov-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024 PFS), the patient experienced MYELITIS TRANSVERSE (Transverse myelitis) (seriousness criteria hospitalization and medically significant). At the time of the report, MYELITIS TRANSVERSE (Transverse myelitis) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Magnetic resonance imaging: MRI's led to diagnosis by a neurologist of transverse myelitis, caused by a lesion on my cervical spine at C4/C5..     For mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Intramuscular use), the reporter did not provide any causality assessments.   Concomitant medication was not provided. On the evening of Nov 15, patient first noticed a sensation of heaviness/weakness in left arm, as she reached for a jug in refrigerator. She did not think it was serious and went to bed without any other symptoms. The next morning (Nov 16), she woke up with an extremely heavy left arm, and elevated blood pressure. She went to urgent care for some initial testing on cardiac symptoms, CT and EKG were clean. But by that time, she had lost mobility and strength all the way up and down her left side and was unable to stand up. She was transported by ambulance to the hospital and was treated with high dose IV steroids for 5 days, and subsequent physical therapy. Her neurologist had indicated that the vaccine likely triggered activation of this disorder, manifested in transverse myelitis.  Company Comment: This is a spontaneous case concerning a 41-year-old female patient with medical history of MOGAD (myelin oligodendrocyte glycoprotein antibody disorder), who experienced the serious (due to medically significant and hospitalization) unexpected, AESI event of Myelitis transverse, which occurred approximately 4 days after a dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) vaccine. It was reported that patient first noticed a sensation of heaviness/weakness in left arm. She went to bed without any other symptoms. The next morning, she woke up with an extremely heavy left arm, and elevated blood pressure. She went to urgent care for some initial testing on cardiac symptoms: CT and EKG were clean. But by that time, she had lost mobility and strength all the way up and down her left side and was unable to stand up. She was transported by ambulance to the hospital and was treated with high dose IV steroids for 5 days, and subsequent physical therapy. Bloodwork revealed that patient had (previously undiagnosed and asymptomatic) antibody disorder called MOGAD (myelin oligodendrocyte glycoprotein antibody disorder). Magnetic resonance imaging led to diagnosis by a neurologist of transverse myelitis, caused by a lesion on my cervical spine at C4/C5 Her neurologist had indicated that the vaccine likely triggered activation of this disorder, manifested in transverse myelitis. The outcome of the event was reported as recovering. The mentioned medical history remains as a confounder. The benefit-risk relationship of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS), vaccine is not affected by this report.